Developing Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry Matthew T. Welling, Lei Liu, Arno Hazekamp, Ashley Dowell, Graham J. King Medical Cannabis & Cannabinoids, 2019, 2, 1–13 Doi : 10.1159/000496868 Abstract The plant genus Cannabis is a prolific producer of unique pharmaceutically relevant metabolites, commonly referred to as cannabinoids. Robust and standardised methods for the quantification of cannabinoids within botanical and drug forms is a critical step forward for an emerging Cannabis- based pharmaceutical industry, which is poised for rapid expansion. Despite a growing body of analytical methods for the quantification of cannabinoids, few have [...]
Lire la suiteCannabinoids in Gynecological Diseases Petra Luschnig, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 14-21 Doi : 10.1159/000499164 Abstract The endocannabinoid system (ECS) is a multifunctional homeostatic system involved in many physiological and pathological conditions. The ligands of the ECS are the endocannabinoids, whose actions are mimicked by exogenous cannabinoids, such as phytocannabinoids and synthetic cannabinoids. Responses to the ligands of the ECS are mediated by numerous receptors like the classical cannabinoid receptors (CB1 and CB2) as well as ECS-related receptors, e.g., G protein-coupled receptors 18 and 55 (GPR18 and GPR55), transient receptor potential ion channels, and nuclear peroxisome proliferator-activated receptors. The ECS regulatesalmost all levels of [...]
Lire la suiteGPR55-Mediated Effects in Colon Cancer Cell Lines Carina Hasenoehrl, David Feuersinger, Melanie Kienzl, Rudolf Schicho Medical Cannabis & Cannabinoids, 2019, 2, 22–28 Doi : 10.1159/000496356 Abstract The cannabinoid-responsive G protein-coupled receptor GPR55 and its endogenous ligand L-α lyso-phosphatidylinositol (LPI) have been reported to play a role in several cancers. A proliferation-enhancing effect of GPR55 has been described for several cancer cell lines and LPI has been found elevated in cancer patients. The aim of this study was to investigate whether GPR55 signaling had an effect on the proliferation of colon cancer cell lines. Using cell viability assays and Western blotting, we show that stable overexpression [...]
Lire la suiteA Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers Daniel Perkins · Juliet Butler · Katherine Ong · Tri‑Hung Nguyen · Susan Cox · Barbara Francis · Michelle Mcintosh · Brian Lilley European Journal of Drug Metabolism and Pharmacokinetics, 2020, Doi : 10.1007/s13318-020-00624-6 Abstract Background : There is increasing interest in the use of purified cannabidiol (CBD) as a treatment for a wide range of conditions due to its reported anti-inflammatory, anxiolytic, antiemetic and anticonvulsant properties. Objective : The objective of this study was to assess the [...]
Lire la suiteThe Reemergence of Ketamine for Treatment in Critically Ill Adults Kimberly P. Hurth, Kristen B. Thomas, Michael A. Rudoni Critical Care Medicine, 2020,1-13. Doi : 10.1097/CCM.0000000000004335 Objectives : To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population. Data Sources : A literature review was performed using PubMed evaluating primary literature published until August 2018. Study Selection : Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis. Uses of [...]
Lire la suiteThe 2nd International Annual Congress on Controversies on Cannabis-Based Medicines (Med-Cannabis 2019) Barcelona, Spain, May 23–24, 2019 Abstracts Congress Chairs: Prof. Dr. Med. Winfried Häuser, Klinikum Saarbrücken, Germany Dr. Silviu Brill, Tel Aviv Medical Center, Israel Medical Cannabis & Cannabinoids, 2019, 2, 69–83 Published online: May 13, 2019 Doi : 10.1159/000500623 KRAGER : Basel · Freiburg · Paris · London · New York · Chennai · New Delhi · Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney © 2019 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca P-01 Cannabis and Metals: Soils Need to be Controlled Yann Barguil , Laura Chiaradia Biochemistry and Toxicology Laboratory, Gaston Bourret Territorial Hospital [...]
Lire la suitePrescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado Amalie K. Kropp Lopez, Stephanie D. Nichols, Daniel Y. Chung, Daniel E. Kaufman, Kenneth L. McCall and Brian J. Piper International Journal of Environmental Research and Public Health, 2020, 17, 3251 doi : 10.3390/ijerph17093251 Abstract : There have been dynamic changes in prescription opioid use in the US but the state level policy factors contributing to these are incompletely understood. We examined the association between the legalization of recreational marijuana and prescription opioid distribution in Colorado. Utah and Maryland, two states that had not legalized recreational marijuana, were selected for comparison. Prescription data reported to [...]
Lire la suiteBeneficial Effects of Cannabis on Blood Brain Barrier Function in HIV Ronald J Ellis 1 , Scott Peterson 2 , Mariana Cherner 1 , Erin Morgan 1 , Rachel Schrier 1 , Bin Tang 1 , Martin Hoenigl 1 , Scott Letendre 1 , Jenny Iudicello 1 Clinical infectious diseases, 2020 Apr 16, ciaa437. Doi : 10.1093/cid/ciaa437 Abstract Background: HIV infection leads to blood-brain barrier (BBB) dysfunction that does not resolve despite viral suppression on antiretroviral therapy and is associated with adverse clinical outcomes. In preclinical models, cannabis restores BBB integrity. Methods: We studied people with HIV (PWH) and HIV- individuals who had used cannabis [...]
Lire la suiteAstrocytes in rapid ketamine antidepressant action Matjaž Stenovec, Baoman Li, Alexei Verkhratsky, Robert Zorec Neuropharmacology, 2020, 173, 108158 Doi : 10.1016/j.neuropharm.2020.108158 H I G H L I G H T S • Ketamine inhibits calcium signalling and enhances cAMP production in astroglia. • Ketamine suppresses exocytosis of gliosignalling molecules and Kir4.1. • Ketamine elevates cholesterol content in the plasmalemma specifically in astrocytes. A B S T R A C T Ketamine, a general anaesthetic and psychotomimetic drug, exerts rapid, potent and long-lasting antidepressant effect, albeit the cellular and molecular mechanisms of this action are yet to be discovered. Besides targeting neuronal NMDARs fundamental for synaptic transmission, ketamine affects the [...]
Lire la suiteAntidepressant mechanisms of ketamine: Focus on GABAergic inhibition Bernhard Luscher, Mengyang Fenga, Sarah J. Jefferson Advances in Pharmacology, 2020 doi : 10.1016/bs.apha.2020.03.002 Contents 1. Introduction 3 2. Molecular targets of subanesthetic ketamine and its metabolites 6 3. Insights from ketamine indicate a key role for reduced GABAergic inhibition in the pathophysiology of major depression 7 3.1 Antidepressant efficacy of ketamine is controlled by imbalances between neural excitation and inhibition 7 3.2 Chronic imbalances of neural excitation and inhibition lead to homeostatic downregulation of glutamatergic synapses that compromises normal neuronal communication 9 3.3 Chronic imbalances between neural excitation and inhibition lead to defects in GABAergic inhibition that delimit spontaneous recovery from [...]
Lire la suite